|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
Copyright 1987, 1988, 1989, 2000, 2006, 2008, 2012
NORD is very grateful to Brian Weinshenker, MD, FRCP(C), Professor of Neurology, Mayo Clinic, for assistance in the preparation of this report.
Neuromyelitis optica, also known as Devic disease (DD), is a chronic disorder of nerve tissue characterized by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). There appear to be two forms of this disease. In the classical, but less common monophasic type, one or both optic nerves and the spinal cord are affected by a series of attacks over a short period of time (days or weeks) but, after the initial outburst, there is no recurrence. The second form is more common and is characterized by repeated attacks separated by periods of remission. In this form, the interval between attacks may be weeks, months or years. In its early stages, Devic disease may be confused with multiple sclerosis.
The characteristic symptoms of neuromyelitis optica are either optic neuritis or myelitis; either may occur as the first symptom. Optic neuritis is inflammation, of the optic nerve (optic neuritis) leading to pain inside the eye which rapidly is followed by loss of clear vision (acuity). Usually, only one eye is affected (unilateral) although both eyes may be involved simultaneously (bilateral). Neuromyelitis optica may or may not be preceded by a prodromal upper respiratory infection.
The other cardinal syndrome is inflammation of the spinal cord, a condition known as transverse myelitis because the symptoms tend to affect all motor, sensory and autonomic functions (bladder and bowel) below a certain level on the body. Affected individuals may experience pain in the spine or limbs, and mild to severe paralysis (paraparesis to paraplegia) of the lower limbs, and loss of bowel and bladder control. Deep tendon reflexes may be diminished or absent initially, and later become exaggerated. A variable degree of sensory loss may occur. Affected individuals may also have a stiff neck, back or limb pain, and/or headaches. This syndrome may be indistinguishable from other cases of "idiopathic" transverse myelitis.
Early in the course of the disease, it may be difficult to distinguish between neuromyelitis optica and multiple sclerosis because both may cause optic neuritis and myelitis as symptoms. However, the optic neuritis and myelitis tend to be more severe in neuromyelitis optica; the brain MRI is more commonly normal, and the spinal fluid analysis does not usually show oligoclonal bands in neuromyelitis optica, which are features that help distinguish it from MS.
In most cases of neuromyelitis optica, the initial symptoms of vision loss or paralysis improve with standard treatment with high dose corticosteroids, and partial recovery of vision, motor, sensory, or bladder function occurs. However, in recurring cases, neuromyelitis optica frequently causes significant permanent disturbances of vision and/or spinal cord function leading to blindness or impaired mobility.
Neuromyelitis optica spectrum disorders include limited versions of neuromyelitis associated with positive test for aquaporin-4 autoantibodies and neuromyelitis optica brain syndromes associated with positive test for aquaporin-4 autoantibodies.
Some patients with neuromyelitis optica have only recurrent myelitis or only recurrent optic neuritis. When patients have antibodies to aquaporin-4 with just these manifestations, most investigators would argue that they should be treated as having neuromyelitis optica. Brain lesions may occur in patients with neuromyelitis optica, typically, but not always, in later phases of the disease. Intractable vomiting or hiccups is now a generally accepted specific syndrome of this condition and is the result of inflammation in the dorsal medulla of the brainstem and may be the initial symptom of neuromyelitis optica. Brainstem and hypothalamic syndromes are particularly common, but inflammation of the forebrain may also occur, often associated with prominent brain swelling (edema). Clinicians suspecting this disorder must have a strong index of suspicion for this condition especially in patients with a history of severe myelitis or optic neuritis.
Neuromyelitis optica can also be associated with systemic autoimmune disease.
Greater than 95% of patients with neuromyelitis optica report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which are present in 50% of cases. Neuromyelitis optica is regarded as an autoimmune disease though the exact cause for the autoimmunity is unknown.
Autoimmune disorders occur when the body's natural defenses against disease or invading organisms (such as bacteria), for unknown reasons, suddenly begin to attack healthy tissue. These defenses, for reasons not at all understood, attack proteins in the central nervous system, especially aquaporin-4.
Neuromyelitis optica occurs in individuals of all races. The prevalence of neuromyelitis optica is approximately 1 per 100,00 individuals and seems to be similar worldwide. Relative to MS that it mimics, it occurs with greater frequency in individuals of Asian descent and possibly in individuals of African descent, but the majority of patients with this illness in Western countries are Caucasian. Individuals of any age may be affected, but typically neuromyelitis optica occurs in late middle-aged women. Equal numbers of men and women have the form that does not recur after the initial flurry of attacks, but women are four or five times more likely to be affected than men by the recurring (relapsing) form. Children represent may also be affected by this condition; children more commonly develop brain symptoms at onset and seem to have a higher frequency of monophasic presentation.
Symptoms of the following disorders can be similar to those of neuromyelitis optica. Comparisons may be useful for a differential diagnosis:
Acute disseminated encephalomyelitis (postinfectious encephalitis) is a central nervous system disorder characterized by inflammation of the brain and spinal cord caused by damage to the fatty sheath surrounding the nerves. This can occur spontaneously, but usually follows a viral infection or inoculation such as a bacterial or viral vaccine.
Multiple sclerosis is a chronic disease of the brain and spinal cord (central nervous system) which may be progressive, relapsing and remitting, or stable. The pathology of MS consists of small lesions called plaques that form randomly throughout the brain and spinal cord. In these plaques, the fatty sheath surrounding nerves is lost, which prevents proper transmission of nervous system signals and thus result in a variety of neurological symptoms. Most individuals with MS have a near normal life span. Symptoms often include visual difficulties as well as speech impairment, abnormal skin sensations or numbness, gait disturbance, and difficulties with bladder and bowel function. In a small number of cases, selective involvement of the optic nerves and spinal cord may occur in early stages of MS, but in these situations rarely would the spinal cord information extend over long segments of the spinal cord as occurs in neuromyelitis optica. (For more information on this disorder, choose "Multiple Sclerosis" as your search term in the Rare Disease Database.)
Systemic lupus erythematosus (also known as lupus) is an inflammatory connective tissue disease that can affect many parts of the body including the joints, skin and internal organs. Lupus is a disease of the body's immune system, most often striking young women between the ages of fifteen and thirty-five years. (For more information on this disorder, choose "Lupus" as your search term in the Rare Disease Database.) Transverse myelitis and optic neuritis have been reported to occur in patients with systemic lupus erythematosus, but recent research demonstrates that the a high proportion of such individuals have the NMO-IgG antibody, and likely have coexisting neuromyelitis optica.
Paraneoplastic disorders are conditions in which patients develop inflammation or cell injury caused by autoimmune reactions to a cancer that leads to production of autoantibodies or cell-mediated autoimmunity. In some paraneoplastic syndromes, particularly those associated with collapsin response mediated protein 5 (CRMP5), optic neuritis and extensive myelitis may occur that may closely simulate neuromyelitis optica.
A diagnosis of neuromyelitis optica is made based upon a detailed patient history, a thorough clinical evaluation, identification of characteristic physical findings, and a variety of specialized tests. Such tests include blood tests, examination of cerebrospinal fluid (CSF), spinal taps, or x-ray procedures such as magnetic resonance imaging (MRIs) or computed tomography (CT or CAT) scans. A blood test, NMO-IgG, has been recently discovered which is highly specific and moderately sensitive for neuromyelitis optica. It has been shown that it detects antibodies that are specific for an astrocyte protein, aquaporin-4. This is very helpful to request this test at the first significant suspicion of neuromyelitis optica, as it is frequently positive at the time of the very first symptom even before a confident clinical diagnosis is possible. Successful diagnosis of neuromyelitis optica depends on distinguishing it from MS.
For acute attacks, the standard treatment is high-dose intravenous corticosteroids, typically methylprednisolone. Plasma exchange may be effective in patients who experience acute severe attacks that do not response to intravenous corticosteroids. This procedure involves removing some blood and mechanically separating the blood cells from the fluid (plasma). Blood cells are then mixed with a replacement solution and returned to the body.
For long-term suppression of the disease, no specific treatment has been studied in controlled clinical trials, but a variety of immunosuppressive drugs are regarded by many clinicians as first-line therapy. Corticosteroids, azathioprine, mycophenolate mofetil and rituximab are the treatments most widely prescribed treatments. Typically, azathioprine or mycophenolate mofetil are prescribed along with low doses of corticosteroids. Rituximab has been shown to be helpful in two retrospective studies, including in patients who fail first-line immunosuppressive treatments. Immunomodulatory drugs for multiple sclerosis are ineffective, and in the case of interferon beta, there is some evidence that suggest that they may be harmful.
Symptom treatment may also involve the use of low doses of carbamazepine to control paroxysmal (sudden) tonic spasms that often occur during attacks of neuromyelitis optica and antispasticity agents to treat long term complication of spasticity that frequently develops in those with permanent motor deficits.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
22100 Gratiot Ave.
Eastpointe, MI 48021
Phone #: 586-776-3900
800 #: 800-598-4668
Home page: http://www.aarda.org/
Phone #: N/A
800 #: N/A
Home page: http://www.autoimmunitycommunity.org
PO Box 8126
Gaithersburg, MD 20898-8126
Phone #: 301-251-4925
800 #: 888-205-2311
Home page: http://rarediseases.info.nih.gov/GARD/
8910 University Center Lane, Suite 725
San Diego, CA 92122
Phone #: 858-638-7638
800 #: N/A
Home page: http://www.guthyjacksonfoundation.org
31 Center Dr
Bethesda, MD 20892-2510 United States
Phone #: 301-496-5248
800 #: --
Home page: http://www.nei.nih.gov/
P.O. Box 5801
Bethesda, MD 20824
Phone #: 301-496-5751
800 #: 800-352-9424
Home page: http://www.ninds.nih.gov/
1787 Sutter Parkway
Powell, OH 43065-8806 USA
Phone #: 614-766-1806
800 #: --
Home page: http://www.myelitis.org
Kasper, DL, Fauci AS, Longo DL, et al., eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill Companies; 2005:2444, 2470.
Weinshenker B. In NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott, Williams & Wilkins; 2003:567.
Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659-66.
Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383-92.
Shimizu Jun, Hatanaka Yuki, Hasegawa Michiko, et al. IFN ß-1b may severely exacerbate Japanese optico-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423-7.
Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010;68(5):757-61.
Collongues N, Marignier R, Zephir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology. Neurology. 2010;75(12):1084-8.
Matiello M, Kim HJ, Kim W, et al. Familial neuromyelitis optica. Neurology. 2010;75(4):310-5.
Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. Journal of Neurology. 2009;256(1):35-44.
McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008;71(2):93-100.
Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Archives of Neurology. 2008;65(11):1443-8.
Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. Journal of Neurology. 2008;255(2):305-7.
Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis Optica and non-organ-specific Autoimmunity. Archives of Neurology. 2008;65(1):78-83.
Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol. 2008;63(4):531-4.
Nakashima I, Fukazawa T, Ota K, et al. Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. Journal of Neurology. 2007;254(4):488-92.
Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. MS. 2007;13(2):256-9.
Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis Optica: Changing Concepts J. Neuroimmunol. 2007;187: 126-138 (DOI: 10.1016/j.jneuroim.2007.04.009.)
Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis Optica. Curr. Opin. Neurol. 2007;20: 255-260.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6: 805-815.
Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA. NMO-IgG: A specific biomarker for neuromyelitis optica. Dis Markers. 2006;22(4):197-206.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-89.
Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol res. 2006;28;348-53.
Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. Pharmacol Ther. 2006;112(1):57-70.
Wingerchuk D. Neuromyelitis optica. Int MS J. 2006;13:42-50.
Jacobi C, Stingele K, Kretz R, Hartmann M, Storch-Hagenlacher B, Breitbart A, Wildemann B. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. Lupus. 2006;63:390-96.
Weinshenker BG, Wingerchuk DM, Vukusic S, Limbo L, Pittock SJ, Lucchinetti CF, Lennon VA. Ann Neurol. 2006;59:566-69.
Kira J. Multiple sclerosis in the Japanese population. Lancet Neurology. 2003;2(2):117-27.
Gold R, Linington C. Devic's disease: bridging the gap between laboratory and clinic. Brain. 2002;125:1425-27.
Transverse Myelitis Association. Neuromyelitis Optica. http://www.myelitis.org/nmo.htm. Last Updated December 10, 2011. Accessed February 15, 2012.
Report last updated: 2012/03/08 00:00:00 GMT+0